Cambridge, MA, United States of America

Marc A Caporini

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 15(Granted Patents)


Location History:

  • Thousand Oaks, CA (US) (2022)
  • Cambridge, MA (US) (2024)
  • Belmont, MA (US) (2024)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Marc A. Caporini

Introduction

Marc A. Caporini is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds targeting KRAS G12C mutations. With a total of 6 patents to his name, Caporini's work has been instrumental in advancing cancer treatment options.

Latest Patents

One of his latest patents focuses on the "Synthesis of key intermediate of KRAS G12C inhibitor compound." This invention relates to an improved, efficient, and scalable process to prepare intermediate compounds, such as compound 5M. These compounds are crucial for synthesizing drugs that target KRAS G12C mutations, which are associated with various cancers.

Career Highlights

Marc A. Caporini has established a successful career at Amgen Inc., a leading biotechnology company. His innovative approaches and dedication to research have positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Throughout his career, Caporini has collaborated with several talented individuals, including Andrew Thomas Parsons and William Powazinik. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Marc A. Caporini's contributions to the field of pharmaceutical chemistry and his innovative patents demonstrate his commitment to advancing medical science. His work continues to impact the development of targeted therapies for cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…